GLP1R and type 1 diabetes mellitus: According to report that GLP-1 receptors are detected in multiple cells within the immune system [13], GLP-1 or exendin-4 collectively suggests that current incretin therapies may have multiple beneficial effects in patients with type 1 diabetes, including improved glycemic control via multiple mechanisms.